Madison Asset Management LLC Decreases Position in Globus Medical, Inc. $GMED

Madison Asset Management LLC trimmed its position in Globus Medical, Inc. (NYSE:GMED) by 43.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,151 shares of the medical device company’s stock after selling 11,599 shares during the quarter. Madison Asset Management LLC’s holdings in Globus Medical were worth $1,323,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of GMED. Advisory Services Network LLC acquired a new stake in shares of Globus Medical in the 3rd quarter valued at $26,000. EverSource Wealth Advisors LLC raised its holdings in shares of Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares in the last quarter. SBI Securities Co. Ltd. raised its holdings in shares of Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares in the last quarter. First Horizon Corp acquired a new stake in shares of Globus Medical in the 3rd quarter valued at $31,000. Finally, Parallel Advisors LLC raised its holdings in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Price Performance

Shares of NYSE:GMED opened at $77.25 on Friday. The company’s fifty day moving average price is $88.05 and its 200 day moving average price is $87.16. Globus Medical, Inc. has a 12 month low of $51.79 and a 12 month high of $101.40. The firm has a market capitalization of $10.45 billion, a P/E ratio of 17.96, a P/E/G ratio of 1.56 and a beta of 1.00.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same period last year, the business earned $0.68 EPS. Globus Medical’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, sell-side analysts anticipate that Globus Medical, Inc. will post 4.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on GMED. Needham & Company LLC raised their price objective on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. TD Cowen upgraded shares of Globus Medical to a “strong-buy” rating in a report on Tuesday, January 27th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Barclays raised their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, Globus Medical presently has an average rating of “Moderate Buy” and a consensus price target of $106.36.

Insider Buying and Selling

In related news, EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 18.38% of the stock is owned by corporate insiders.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.